home / stock / aps:cc / aps:cc news

APS:CC News and Press, Aptose Biosciences Inc.

Stock Information
Company Name: Aptose Biosciences Inc.
Stock Symbol: APS:CC
Market: TSXC
Website: aptose.com
Menu
APS:CC APS:CC Quote APS:CC Short APS:CC News APS:CC Articles APS:CC Message Board
Get APS:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
APS:CC - Aptose Announces Receipt of Deficiency Notice from Nasdaq

SAN DIEGO and TORONTO, July 19, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, t...
APS:CC - Canadian Companies Moving the Markets, Evening edition
Wed, Jul 17, 2024 as of 4:00 pm ET

A look at the top 10 most actives in Canada BetaPro Natural Gas Leveraged Daily Bull ETF (HNU) fell 11.1% to $2.63 on volume of 13,371,978 shares Baytex Energy Corp. (BTE) fell 1.4% to $5.08 on volume of 13,132,263 shares Enbridge Inc. (ENB) rose 0.7% to $49.58 on volume of 10,761,843 sha...

APS:CC - Canadian Companies Moving the Markets, Morning edition
Thu, Jun 20, 2024 as of 10.00 am ET

A look at the top 10 most actives in Canada Calibre Mining Corp. (CXB) fell 2.9% to $1.835 on volume of 79,684,444 shares Canadian Natural Resources Limited (CNQ) rose 1.6% to $48 on volume of 6,456,525 shares Alaris Equity Partners Income Trust 5.50% convertible unsecured subordinated de...

APS:CC - Aptose Announces Results from Annual and Special Meeting of Shareholders

SAN DIEGO and TORONTO, June 18, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies,...
APS:CC - Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress

TUS Monotherapy and TUS+Venetoclax (VEN) Doublet Therapy Show Broad Clinical Activity and Strong Safety Data in relapsed or refractory (R/R) Acute Myeloid Leukemia (AML) and Differentiate TUS from other Investigational Drugs in AML TUS Monotherapy and TUS+VEN Doublet Therapy Active in...

APS:CC - Canadian Companies Moving the Markets, Evening edition
Tue, Jun 04, 2024 as of 4:00 pm ET

A look at the top 10 most actives in Canada Park Lawn Corporation (PLC) rose 58.6% to $25.93 on volume of 19,860,058 shares BetaPro Natural Gas Leveraged Daily Bull ETF (HNU) fell 10.1% to $4.65 on volume of 14,334,741 shares Suncor Energy Inc. (SU) fell 2.9% to $51.47 on volume of 14,202...

APS:CC - Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

SAN DIEGO and TORONTO, June 03, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, t...
APS:CC - Canadian Companies Moving the Markets, Morning edition
Fri, May 31, 2024 as of 10.00 am ET

A look at the top 10 most actives in Canada iShares S&P/TSX 60 Index ETF (XIU) rose 0.5% to $33.45 on volume of 14,006,612 shares iShares Core S&P/TSX Capped Composite Index ETF (XIC) rose 0.6% to $35.48 on volume of 7,924,403 shares Suncor Energy Inc. (SU) rose 1.3% to $55.28 on ...

APS:CC - Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

SAN DIEGO and TORONTO, May 31, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, to...

APS:CC - Aptose Reports Results for the First Quarter 2024

TUS+VEN+HMA Triplet Protocol in 1L Therapy for Newly Diagnosed AML was Submitted to the FDA During Q1 and is Now Being Activated at Clinical Sites TUS+VEN+HMA Triplet 1L Therapy for Newly Diagnosed AML is Supported by Extensive TUS and TUS+VEN Data from Completed Trials with R/R AML ...
Next 10